G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
115 hedge funds and large institutions have $358M invested in G1 Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 13 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
14% more call options, than puts
Call options by funds: $2.8M | Put options by funds: $2.47M
1% more funds holding
Funds holding: 114 → 115 (+1)
34% less capital invested
Capital invested by funds: $541M → $358M (-$184M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.3M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$13.4M |
| 3 |
JP Morgan Chase
New York
|
+$5.92M |
| 4 |
Goldman Sachs
New York
|
+$3.98M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$8.82M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.77M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.83M |
| 4 |
Morgan Stanley
New York
|
-$3.68M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.6M |
GTHX Hedge Fund Activity: Q3 2021 in Review
115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2021, worth a combined $358M — down 34% from $541M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GTHX positions and 13 closed out — a net gain of 2 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was State Street, adding an estimated $26.3M. The largest seller was Two Sigma Investments, cutting an estimated $8.82M.
- 115 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2021, up from 114 in Q2 2021.
- Funds reported $358M of G1 Therapeutics, Inc. Common Stock stock for Q3 2021, down 34% quarter-over-quarter.
- 15 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2021 and 13 closed out, a net change of +2 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2021 was State Street, an estimated $26.3M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2021 was Two Sigma Investments, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2021.